Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02111863 | Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2017 | clinicaltrials |
| NCT02625337 | Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients(IMPemBra) | unknown | Phase 2 | 32 | The Netherlands Cancer InstituteOTHER | 1 | Sep 15, 2017 |
| clinicaltrials |
| NCT01696045 | Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma | terminated | Phase 2 | 14 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 29, 2017 | clinicaltrials |
| NCT01833767 | Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma | withdrawn | Phase 2 | 0 | Western Regional Medical CenterOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01138410 | Study of a DNA Immunotherapy to Treat Melanoma | terminated | Phase 1 / Phase 2 | 35 | Scancell LtdINDUSTRY | 1 | Aug 21, 2017 | clinicaltrials |
| NCT01042366 | Dendritic Cells (DC) Vaccine for Metastatic Melanoma | terminated | Phase 2 | 16 | John KirkwoodOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00521001 | Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery | completed | Phase 2 | 49 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 14, 2017 | clinicaltrials |
| NCT01252251 | RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01271907 | Drosophila-generated CTL | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2017 | clinicaltrials |
| NCT02663258 | A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)(ADAPTeM) | withdrawn | Phase 2 | 0 | Royal Marsden NHS Foundation TrustOTHER | 0 | Aug 1, 2017 | clinicaltrials |
| NCT01253564 | A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases | completed | Phase 2 | 24 | Hoffmann-La RocheINDUSTRY | 1 | Jul 31, 2017 | clinicaltrials |
| NCT00107718 | Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma | completed | Phase 2 | 64 | GlaxoSmithKlineINDUSTRY | 2 | Jul 27, 2017 | clinicaltrials |
| NCT01143402 | Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2017 | clinicaltrials |
| NCT00949702 | A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma | completed | Phase 2 | 132 | Hoffmann-La RocheINDUSTRY | 2 | Jul 25, 2017 | clinicaltrials |
| NCT00434252 | A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma(BEAM) | completed | Phase 2 | 214 | Genentech, Inc.INDUSTRY | 0 | Jul 18, 2017 | clinicaltrials |
| NCT00849875 | A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients | terminated | Phase 2 | 48 | GlaxoSmithKlineINDUSTRY | 2 | Jul 12, 2017 | clinicaltrials |
| NCT00062036 | Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 33 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00925132 | Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat | terminated | Phase 1 / Phase 2 | 39 | University of IowaOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01701037 | Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery | terminated | Phase 2 | 13 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 23, 2017 | clinicaltrials |
| NCT00610857 | Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma | completed | Phase 2 | 37 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00125749 | Vaccination of Patients With Stage IV Melanoma With Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Baylor Research InstituteOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT00397982 | Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma(Mel47) | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jun 9, 2017 | clinicaltrials |
| NCT01395121 | A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread(NICAM) | completed | Phase 2 | 29 | Institute of Cancer Research, United KingdomOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT01586195 | Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E | terminated | Phase 2 | 31 | Genentech, Inc.INDUSTRY | 1 | May 25, 2017 | clinicaltrials |
| NCT01676779 | mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma(DC-MEL) | completed | Phase 2 | 88 | Universitair Ziekenhuis BrusselOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00831545 | Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064) | completed | Phase 2 | 162 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 9, 2017 | clinicaltrials |
| NCT02023710 | Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma | unknown | Phase 2 | 182 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT02452294 | Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)(BUMPER) | unknown | Phase 2 | 22 | University Hospital TuebingenOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT00093119 | Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma | completed | Phase 2 | 75 | CelgeneINDUSTRY | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01164007 | A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma | completed | Phase 2 | 40 | Hoffmann-La RocheINDUSTRY | 1 | Apr 21, 2017 | clinicaltrials |
| NCT00871481 | Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT00940004 | Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients | completed | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01530698 | Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients | completed | Phase 1 / Phase 2 | 28 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01551693 | STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT01754376 | Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma | terminated | Phase 2 | 6 | Massachusetts General HospitalOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | terminated | Phase 1 / Phase 2 | 9 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00976573 | Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 149 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01026324 | Dinaciclib in Treating Patients With Stage III-IV Melanoma | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00707161 | Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT03095079 | Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma | unknown | Phase 2 | 70 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00482911 | Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma | terminated | Phase 2 | 12 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 27, 2017 | clinicaltrials |
| NCT00060333 | Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma | completed | Phase 2 | 20 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 17, 2017 | clinicaltrials |
| NCT01781026 | Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases | completed | Phase 2 | 2 | Yale UniversityOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00601861 | Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer | terminated | Phase 2 | 1 | Novo Nordisk A/SINDUSTRY | 1 | Mar 1, 2017 | clinicaltrials |
| NCT01705392 | Bevacizumab vs Dacarbazine in Metastatic Melanoma | terminated | Phase 2 | 2 | Haukeland University HospitalOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT00003895 | Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00553306 | Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00450372 | Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 38 | University of MiamiOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT02400385 | A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma | withdrawn | Phase 2 | 0 | California Pacific Medical Center Research InstituteOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT00550654 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | terminated | Phase 2 | 1 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jan 13, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2017source: clinicaltrials